GIA
CYTK icon

Gateway Investment Advisers’s Cytokinetics CYTK Stock Holding History

Gateway Investment Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$435K Buy
+6,605
New +$504K ﹤0.01% 696

Other funds holding CYTK

MCP
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
VC
Veracity Capital Atlanta, Georgia $372M AUM 32.95% 1-Year Est. Return
BCG
Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.15B AUM 7.83% 1-Year Est. Return

Gateway Investment Advisers's CYTK Position: Q3 2026 in Review

Gateway Investment Advisers opened a new position in Cytokinetics (CYTK) in Q3 2026: 6,605 shares worth $435K. The stake represents ﹤0.01% of the portfolio and ranks #696 among its holdings.

13 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

  • Gateway Investment Advisers held 6,605 shares of Cytokinetics worth $435K as of Q3 2026.
  • Cytokinetics was a new Gateway Investment Advisers position in Q3 2026.
  • Cytokinetics made up ﹤0.01% of Gateway Investment Advisers's portfolio in Q3 2026, its #696 holding.
  • 13 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on Gateway Investment Advisers's 13F filing for Q3 2026, filed 13 Oct 2026.